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MaOBJECTIVES The authors aimed to compare long-term data of an ultrathin cobalt-chromium stent with passive silicon
carbide coating and an active biodegradable polymer that releases sirolimus (O-SES) (Orsiro, BIOTRONIK, Bülach,
Switzerland) with the durable polymer-based Xience Prime everolimus-eluting stent (X-EES) (Abbott Vascular,
Santa Clara, California).
BACKGROUND Biodegradable polymer stents have been developed aiming to overcome long-term detrimental effects
of durable polymer stents, ultimately leaving a bare-metal stent in the vessel.
METHODS This multicenter, assessor-blinded trial randomized 452 patients with 505 lesions to either O-SES or X-EES in
a 2:1 fashion. Endpoints at 5 years were target lesion failure (TLF), its components, and stent thrombosis.
RESULTS TLF occurred in 10.4% (n¼ 30) of O-SES patients versus 12.7% (n¼ 19) of X-EES patients (p ¼ 0.473), overall
stent thrombosis occurred in 0.7% (n ¼ 2) versus 2.8% (n ¼ 4) (p ¼ 0.088), and deﬁnite stent thrombosis in 0% versus
0.7% (n ¼ 1) (p ¼ 0.341). Post hoc analysis was performed in diabetic patients (n ¼ 128) and vessels#2.75 mm (n ¼ 259).
In diabetic patients, the O-SES group had numerically more target lesion revascularizations (13.5% vs. 4.5%; p ¼ 0.138),
but fewer cardiac deaths (1.3% vs. 6.9%; p ¼ 0.089) and stent thrombosis (0% vs. 6.9%; p ¼ 0.039). In small vessels,
the O-SES group had a signiﬁcantly lower 5-year mortality (3.7% vs. 11.3%; p ¼ 0.022).
CONCLUSIONS At 5 years, the biodegradable polymer O-SES demonstrated low TLF rates comparable to the
durable polymer X-EES, conﬁrming its long-term safety and performance. Particularly encouraging is the absence of
deﬁnite stent thrombosis. (J Am Coll Cardiol Intv 2018;11:995–1002) © 2018 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2018.04.014
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ABBR EV I A T I ON S
AND ACRONYMS
ASA = acetylsalicylic acid
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
HR = hazard ratio
IQR = interquartile range
O-SES = Orsiro sirolimus-
eluting stent(s)
ST = stent thrombosis
TLF = target lesion failure
TLR = target lesion
revascularization
X-EES = Xience Prime
everolimus-eluting stent(s)
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996C ontinued efforts to improve out-comes after percutaneous coronaryinterventions using drug-eluting
stents (DES) led to the design of DES with
biodegradable polymers. Because durable
polymers have been associated with local
vascular inﬂammatory reactions and stent
thrombosis (ST), the concept of a biodegrad-
able polymer is appealing, eluting the drug
over an appropriate amount of time, ulti-
mately leaving the bare-metal stent in the
vessel (1).
The use of biodegradable polymer stents
theoretically is expected to show long-term
beneﬁts. In a ﬁrst step, the novel technol-
ogy had to prove its noninferiority to a
contemporary ﬁrst-in-class durable polymer
stent. In a second step, potential long-termbeneﬁts shall be assessed (2).SEE PAGE 1003The Orsiro DES (O-SES) (BIOTRONIK, Bülach,
Switzerland) is a ultrathin cobalt-chromium stent (60-
mm struts) passively coated with amorphous silicon
carbide. The active coating consists of a biodegradable
poly-L-lactic acid polymer from which sirolimus is
released. Published 1-year outcomes of the BIOFLOW-
II (Study of the Orsiro Drug Eluting Stent System)
study showed noninferiority to the everolimus-
eluting Xience stent (X-EES) (Abbott Vascular, Santa
Clara, California) (3). Those results were corroborated
by several randomized controlled trials, in which
Orsiro was noninferior to contemporary everolimus
and zotarolimus durable polymer stents and biolimus-
eluting biodegradable polymer stents (2,4–6). More-
over, in the recently published BIOFLOW-V trial,
Orsiro-treated patients had signiﬁcantly lower 12-
month target lesion failure (TLF), target vessel
myocardial infarction, and late ST rates compared
with the durable polymer X-EES (7). Herein, we report
5-year outcomes of the BIOFLOW-II study.
METHODS
STUDY DESIGN. The study design has been published
previously (3) and is posted on ClinicalTrials.gov
(NCT01356888). In brief, the BIOFLOW-II study is a ran-
domized, multicenter, assessor-blind, noninferiority
trial comparing the biodegradable polymer–based
O-SES with the durable polymer–based X-EES.
Main inclusion criteria were de novo lesions with a
maximum length of 26 mm and a reference vessel
diameter from 2.25 to 4.0 mm by visual estimate
suitable for coronary stent implantation. Mainexclusion criteria were evidence of myocardial
infarction within 72 h before the procedure, unpro-
tected left main disease of >50% diameter stenosis,
3-vessel coronary artery disease, evidence of thrombus
within the target vessel, heavily calciﬁed lesions, and
ostial lesions within 5 mm of the coronary ostium.
Patients were randomly allocated to treatment
with O-SES or X-EES in a 2:1 ratio. Both stent types
were available in diameters from 2.25 to 4.0 mm. Dual
antiplatelet therapy (DAPT) was recommended for 6
months post-procedure and acetylsalicylic acid (ASA)
lifelong, according to the current European Society of
Cardiology/European Association for Cardio-Thoracic
Surgery guidelines on myocardial revascularization
(8).
Follow-ups were scheduled at 30 days; 6, 9, and 12
months; and annually thereafter up to 5 years. All
serious adverse events and adverse device effects
were adjudicated by an independent clinical events
committee. The study was performed in accordance
with ISO14155:2011 and the Declaration of Helsinki,
and was approved by all institutional ethics commit-
tees. All patients provided written informed consent.
STUDY ENDPOINTS AND DEFINITIONS. The primary
endpoint was in-stent late lumen loss at 9 months
after stent implantation, assessed by quantitative
coronary angiography of an independent core labo-
ratory. Secondary angiographic endpoints, intravas-
cular and optical coherence tomography, procedure
and device success, and 1-year safety outcomes have
been reported previously (3). Secondary endpoints
beyond 1 year were TLF, a composite of cardiac death,
target vessel myocardial infarction (9), and clinically
driven target lesion revascularization (TLR); target
vessel failure, a composite of cardiac death, target-
vessel myocardial infarction, and clinically driven
target vessel revascularization; a composite of all-
cause mortality and myocardial infarction; and deﬁ-
nite ST (10).
STATISTICAL ANALYSIS. This study was powered for
noninferiority related to the primary endpoint, in-
stent late lumen loss at 9 months (3). Patients were
analyzed in the groups they were allocated to,
regardless of the treatment actually received (inten-
tion to treat). Continuous variables are presented as
mean  SD or median (interquartile range [IQR]) and
categorical variables as number (percent). Chi-square
test was used for comparison. Clinical outcomes were
presented as Kaplan-Meier estimates and groups
compared using the log-rank test. The Cox propor-
tional hazards model was used to estimate hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) for
between-group comparison. In a post hoc analysis,
TABLE 1 Baseline Clinical Characteristics
O-SES
(n ¼ 298)
X-EES
(n ¼ 154)
p
Value
Age, yrs 62.7  10.4 64.8  9.2 0.032
Male 233 (78.2) 115 (74.7) 0.400
Cardiac risk factors
Diabetes mellitus 84 (28.2) 44 (28.6) 0.932
Insulin dependent 18 (21.4) 15 (34.1) 0.120
Hypertension 231 (77.5) 119 (77.3) 0.953
Hypercholesterolemia 202 (67.8) 113 (73.4) 0.220
History of myocardial infarction 90 (30.2) 31 (20.1) 0.022
Prior coronary intervention 128 (43.0) 55 (35.7) 0.137
Cancer 16 (5.4) 10 (6.5) 0.627
Values are mean  SD or n (%).
O-SES ¼ Orsiro sirolimus-eluting stent; X-EES ¼ Xience everolimus-eluting
stent.
FIGURE 1 Angina Status at Baseline and 5-Year Follow-Up
At 5-year follow-up, 97.0% of Orsiro sirolimus-eluting stent (O-SES) patients were
symptom-free, 2.2% had stable angina, 0.4% had unstable angina, and 0.4% docu-
mented silent ischemia; and 98.5% of Xience everolimus-eluting stent (X-EES) patients
were symptom free and 1.5% had stable angina.
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997the subgroups of diabetic patients and small
lesions #2.75 mm were assessed. The statistical ana-
lyses were carried out using SAS 9.4 (SAS Institute,
Cary, North Carolina).
RESULTS
Between July 2011 and March 2012, 452 patients were
randomized in 24 centers in 8 European countries. Of
those, 298 patients with 332 lesions were allocated to
treatment with the O-SES and 154 patients with 173
lesions to the X-EES. At 5 years, 8 patients (2.7%) in
the O-SES group had withdrawn consent, and another
8 (2.7%) were lost to follow-up, whereas 6 patients
(3.9%) of the X-EES group withdrew consent, and 2
(1.3%) were lost to follow-up.
Baseline data are provided in Table 1. By core lab-
oratory assessment, mean reference vessel diameter
was 2.78  0.49 mm for O-SES and 2.75  0.49 mm for
X-EES, mean lesion length was 13.36  6.82 mm and
13.65  5.58 mm, and type B2/C lesions presented in
28.2% and 22.2% of lesions, respectively. All subjects
received the allocated study stent (100% device suc-
cess). At 9-month follow-up, in-stent late lumen loss
was 0.10  0.32 for O-SES versus 0.11  0.29 mm for
X-EES (pnoninferiority <0.0001).
At 5-year follow-up, 24.7% (66 of 267) of patients in
the O-SES group received dual or triple antiplatelet
therapy versus 14.4% (19 of 132) in the X-EES group
(p ¼ 0.018). Of the overall 85 patients, 75.3% (n ¼ 64)
received ASA plus clopidogrel, 11.8% (n ¼ 10) received
ASA plus prasugrel, 7.1% (n ¼ 6) received ASA plus
ticagrelor, and 5.9% (n¼ 5) received triple therapywith
ASA, clopidogrel, andprasugrel (n¼4) or ticagrelor (n¼
1)without adifferenceamong thegroups.Onsingle-use
ASA only were 65.5% (175 of 267) in the O-SES group
versus 73.5% (97 of 132) in the X-EES group (p ¼ 0.109),and a few patients received single-dose clopidogrel
(n ¼ 12), prasugrel (n ¼ 4), or ticagrelor (n ¼ 2).
The angina status was similar among the groups,
and nearly all patients were free of ischemic symp-
toms at 5 years (Figure 1).
Median follow-up time was 1,825 days (IQR: 1,815
to 1,831 days) for O-SES and 1,823 days (IQR: 1,813 to
1,830 days) for X-EES. At 1 year, TLF estimates were
6.5% (95% CI: 4.2% to 10.0%) in the O-SES group
versus 7.9% (95% CI: 4.6% to 13.5%) in the X-EES
group, and at 5 years, rates were 10.4% (95% CI: 7.4%
to 14.5%) versus 12.7% (95% CI: 8.3% to 19.3%;
p ¼ 0.473). Five-year mortality was numerically lower
in the O-SES group (4.9% [95% CI: 2.9% to 8.1%] vs.
9.5% [95% CI: 5.8% to 15.6%]; HR: 0.51 [95% CI: 0.24
to 1.07]; p ¼ 0.069), as was the rate of overall ST (0.7%
[95% CI: 0.2% to 2.8%] vs. 2.8% [95% CI: 1.1% to
7.4%]; HR: 0.25 [95% CI: 0.05 to 1.39]; p ¼ 0.088,
thereof 0% and 0.7% [95% CI: 0.1% to 5.0%];
p ¼ 0.341, were deﬁnite ST) (Table 2, Figure 2).
DIABETIC AND SMALL VESSEL SUBGROUPS. For
both, diabetes (n ¼ 128) and small vessels (n ¼ 259),
groups were well balanced. The only signiﬁcant dif-
ference in the diabetic subgroup was less frequent
baseline congestive heart failure in O-SES compared
with X-EES patients (13.1% vs. 27.3%; p ¼ 0.047). The
small vessel (#2.75 mm in diameter) group had fewer
left circumﬂex lesions (22.7% vs. 37.6%; p ¼ 0.005)
and longer stents implanted (19.3  6.1 mm vs. 17.4 
5.9 mm; p ¼ 0.005) in the O-SES group.
TABLE 2 Kaplan-Meier Estimates of Clinical Outcomes at 5 Years
O-SES X-EES
Hazard Ratio
(95% CI) p Value
Overall, n 298 154
Death 14 (4.9) 14 (9.5) 0.51 (0.24–1.07) 0.069
Cardiac death 5 (1.7) 4 (2.8) 0.64 (0.17–2.39) 0.504
MI, univ. def. 13 (4.5) 9 (6.2) 0.74 (0.32–1.73) 0.487
TV MI, univ. def. 10 (3.4) 5 (3.3) 1.03 (0.35–3.02) 0.953
Clinically indicated TLR 18 (6.3) 10 (6.7) 0.93 (0.43–2.01) 0.850
Clinically indicated TVR 36 (12.6) 15 (10.1) 1.25 (0.68–2.28) 0.465
Coronary artery bypass graft 0 (0.0) 0 (0.0) 1.00 (1.00–1.00) —
Target lesion failure, univ. def. 30 (10.4) 19 (12.7) 0.81 (0.46–1.44) 0.473
Target vessel failure, univ. def. 45 (15.6) 19 (12.7) 0.97 (0.59–1.58) 0.891
Mortality or MI, univ. def. 26 (9.0) 20 (13.4) 0.66 (0.37–1.19) 0.166
Stent thrombosis 2 (0.7) 4 (2.8) 0.25 (0.05–1.39) 0.088
Deﬁnite 0 (0.0) 1 (0.7) — 0.341
Probable 0 (0.0) 0 (0.0) — —
Diabetic subgroup, n 88 44
Death 6 (7.3) 4 (9.1) 0.78 (0.22–2.78) 0.707
Cardiac death 1 (1.3) 3 (6.9) 0.18 (0.02–1.69) 0.089
MI, univ. def. 4 (4.9) 1 (2.4) 2.15 (0.24–19.26) 0.482
TV MI, univ. def. 2 (2.5) 0 (0.0) — 0.545
Clinically indicated TLR 11 (13.5) 19 (4.5) 2.96 (0.66–13.37) 0.138
Clinically indicated TVR 17 (20.8) 4 (9.3) 2.33 (0.79–6.94) 0.116
Target lesion failure, univ. def. 13 (15.9) 5 (11.5) 1.43 (0.51–4.00) 0.498
Target vessel failure, univ. def. 19 (23.3) 7 (16.0) 1.52 (0.64–3.60) 0.344
Mortality or MI, univ. def. 8 (12.1) 4 (9.1) 1.34 (0.42–4.28) 0.617
Stent thrombosis 0 (0.0) 3 (6.9) — 0.039
Deﬁnite 0 (0.0) 0 (0.0) — —
Probable 0 (0.0) 0 (0.0) — —
Small vessels subgroup, n 168 91
Death 6 (3.7) 10 (11.3) 0.33 (0.12–0.90) 0.022
Cardiac death 1 (0.6) 2 (2.2) 0.28 (0.03–3.08) 0.265
MI, univ. def. 8 (4.9) 5 (5.6) 0.86 (0.28–2.63) 0.791
TV MI, univ. def. 6 (3.7) 4 (4.4) 0.81 (0.23–2.86) 0.738
Clinically indicated TLR 14 (8.7) 8 (8.9) 0.97 (0.41–2.32) 0.948
Clinically indicated TVR 25 (15.6) 12 (13.3) 1.16 (0.58–2.31) 0.676
Target lesion failure, univ. def. 18 (11.1) 14 (15.5) 0.69 (0.35–1.40) 0.303
Target vessel failure, univ. def. 27 (16.8) 18 (19.9) 0.80 (0.44–1.46) 0.475
Death or MI, univ. def. 13 (8.0) 14 (15.6) 0.50 (0.23–2.86) 0.066
Stent thrombosis 1 (0.6) 1 (1.1) 0.55 (0.03–8.84) 0.671
Deﬁnite 0 (0.0) 0 (0.0) — —
Probable 0 (0.0) 0 (0.0) — —
Values are n (%) unless otherwise indicated.
CI ¼ conﬁdence interval; MI ¼myocardial infarction; TLR ¼ target lesion revascularization; TVR ¼ target vessel
revascularization; univ. def. ¼ universal deﬁnition.
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998For diabetic patients, 5-year TLF rates were 15.9%
for O-SES versus 11.5% for X-SES (p ¼ 0.498), caused
by a numerical difference in clinically driven TLR
(13.5% vs. 4.5%; p ¼ 0.138), whereas cardiac death was
numerically lower in the O-SES group (1.3% vs. 6.9%;
p ¼ 0.089) as well as ST (0% vs. 6.9%; p ¼ 0.039). In
patients with small vessels#2.75 mm, 5-year TLF rates
were 11.1% versus 15.5% (p ¼ 0.303). This difference
was mainly due to a lower overall death rate in the
O-SES group (3.7% vs. 11.3%; p ¼ 0.022).DISCUSSION
To our knowledge, this is the ﬁrst report of the Orsiro
biodegradable polymer stent at 5 years. The main
ﬁndings of this randomized trial are the excellent
5-year outcomes for both the biodegradable polymer
O-SES and the durable polymer X-EES. Further, even
though the trial was not powered for clinical out-
comes, there was a trend toward less ST in the O-SES
group (0.7% vs. 2.8%; p ¼ 0.088%), which was sig-
niﬁcant in the diabetics subgroup (0% vs. 6.9%;
p ¼ 0.039).
In contrast, the BIOFOLOW-V trial was powered for
noninferiority of TLF at 12 months and included 1,334
randomized patients. It also employed a Bayesian
approach incorporating data from the BIOFLOW-II
and BIOFLOW-IV trials (7). The pooled analysis
revealed a Bayesian posterior probability of 100% that
O-SES was noninferior to X-EES, and of 96.9% that O-
SES is superior to X-EES. Moreover, trial data from the
BIOFLOW-V trial itself showed signiﬁcantly lower
TLF rates (6% vs. 10%; p ¼ 0.0399) and target vessel
myocardial infarction rates (5% vs. 8%; p ¼ 0.0155) in
the O-SES group (note: a more sensitive deﬁnition of
myocardial infarction than in BIOFLOW-II and
BIOSCIENCE was used). The authors postulated that
O-SES establishes “a new standard for new drug-
eluting stent comparison.”
These superior outcomes at 12 months are sur-
prising, as the true beneﬁt of biodegradable polymer
stents is expected to show after complete polymer
dissolution at 12 to 24 months. This is the case in our
series where—in the high-risk subsets of diabetics and
patients with small vessels—the curves start to
diverge beyond 1 year. Likely, the superior 12-month
outcomes of the BIOFLOW-V study are rather
related to other factors such as the ultrathin stent
design (60-mm struts). In a recent State-of-the-Art
paper, Orsiro had the thinnest struts of relevant
contemporary stents, and thinner struts are associ-
ated with better stent delivery and are expected to be
less thrombogenic. Likewise, in the BIOFLOW-V
study, procedure success (deﬁned as diameter
stenosis <30%, using the assigned stent, and no in-
hospital major adverse cardiac event) was signiﬁ-
cantly higher in the O-SES group than in the X-EES
group (94% vs. 90%; p ¼ 0.0191). In addition, the
drug-polymer combination plays a paramount role
(7,11).
Our 5-year outcomes, particularly the very low rate
of 0.7% overall ST and absence of deﬁnite ST in the
O-SES group at 5 years are remarkable. Aside from the
biodegradable polymer, the passive coating with
FIGURE 2 Kaplan-Meier Estimates for TLF, Cardiac Death, CD TLR, and Overall Stent Thrombosis
(A) Overall population. (B) Diabetic patients. (C) Small vessels. Target lesion failure (TLF) was 10.4% for the O-SES and 12.7% for the X-EES.
CD TLR ¼ clinically driven target lesion revascularization; Univ. Def. ¼ universal deﬁnition; other abbreviations as in Figure 1.
Continued on the next page
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999silicone carbide, which is thought to inhibit platelet
adhesion, might have contributed to these outcomes.
Among other things, it is thought to inhibit platelet
adhesion. In more than 1,000 patients enrolled in the
ENERGY (Long Term Safety Proﬁle of the PRO-Kinetic
ENERGY Coronary Stent System in Daily Clinical
Practice) registry using a bare-metal stent with the
same passive coating, deﬁnite ST at 2 years was only
0.6% in diabetic patients (12). Notably in our series,
there were still a reasonable number—24.7% of pa-
tients in the O-SES group and 14.4% in the X-EES
group (p ¼ 0.018)—on DAPT at 5 years. Thereby the
reason for the disparity is unclear, but it is unlikely
to be associated with the device per se. Rather, it may
be a by-chance ﬁnding related to differences in current
comorbidities or anticoagulation regimes.
Our results for O-SES (TLF of 10.4% and absence of
probable or deﬁnite ST) compare well with 5-year
outcomes of other biodegradable polymer stents. Inthe LEADERS (Limus Eluted From A Durable Versus
ERodable Stent Coating) trial, the 5-year TLF rate was
20.0% for the biodegradable polymer biolimus-
eluting BioMatrix Flex stent (Biosensors, Newport
Beach, California) and 23.1% for the ﬁrst-generation
durable polymer sirolimus-eluting Cypher SELECT
stent (Cordis, Miami Lakes, Florida), whereas deﬁnite
or probable ST rates were 3.6% and 5.2%, respectively
(13). In the EVOLVE (Non-inferiority Trial to Assess
the Safety and Performance of the Evolution Coro-
nary Stent) study, TLF was 5.5% in 92 patients treated
with the biodegradable polymer everolimus-eluting
Synergy stent (Boston Scientiﬁc, Marlborough, Mas-
sachusetts) versus 7.2% in patients treated with a
durable polymer everolimus-eluting stent; deﬁnite or
probable stent thrombosis was absent in both groups
(14). In more than 3,000 patients of the NOBORI
registry using the biodegradable, polymer-coated,
biolimus-eluting Nobori stent (Terumo, Tokyo,
FIGURE 2 Continued
Continued on the next page
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1000Japan), the 5-year composite of cardiac death, any
myocardial infarction, and TLR was 10.0%. Deﬁnite or
probable ST occurred in 1.2% (15). In the randomized
COMPARE-II (Abluminal Biodegradable Polymer
Biolimus-Eluting Stent Versus Durable Polymer
Everolimus-Eluting Stent) trial including 2,707 pa-
tients, the 5-year TLF rate was 13.5% for the Nobori
stent and 11.5% for X-EES, and the rate of deﬁnite or
probable ST was 1.5% versus 0.9% (16). Although the
ST rates are very low, they are still higher than in our
series. Correspondingly, in the SORT-OUT VII
(Scandinavian Organization for Randomized Trials
With Clinical OUTcome) randomized trial comparing
more than 2,500 patients, the O-SES had a
signiﬁcantly lower deﬁnite ST rate compared with
the Nobori stent at 1 year (0.4% versus 1.2%; p ¼
0.03). The authors discussed that the slower
polymer degradation (12 to 24 months compared
with 6 to 9 months) and thinner struts (60 to 80 mm
vs. 120 mm) may reduce inﬂammatory response and
the risk of ST (5).Considering the low ST rates for Orsiro, potential
better re-endothelialization of ultrathin struts,
improved polymer durability, and the potential that
slower polymer degradation or thinner struts may
reduce the risk of early ST, a shorter DAPT use may be
reasonable (5,11,17,18). More insights are expected
from the currently enrolling randomized HOST-IDEA
(Harmonizing Optimal Strategy for Treatment of
Coronary Artery Stenosis - Coronary Intervention
With Next Generation Drug-Eluting Stent Platforms
and Abbreviated Dual Antiplatelet Therapy) trial that
compares the ultrathin Orsiro and Coroﬂex ISAR
(B. Braun Melsungen, Berlin, Germany) stents using
3-month versus 12-month DAPT (18).
DIABETIC AND SMALL VESSEL SUBGROUPS.
Orsiro performed well in patients with diabetes and
small lesions. Although in 128 diabetic patients of our
series, the X-EES arm had numerically less TLR (13.5%
for O-SES and 4.5% for X-EES; p ¼ 0.138), that came at
the price of a numerically higher cardiac death rate
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1001(1.3% for O-SES vs. 6.9% for X-EES; p ¼ 0.089) and a
signiﬁcantly higher overall ST rate. Due to its low
strut thickness, Orsiro may be particularly useful in
small vessels. In our series, in 259 patients with small
vessels, the 5-year TLF rate was numerically lower
(11.1% vs. 15.5%; p ¼ 0.303), and there were also
signiﬁcantly fewer deaths (3.7% vs, 11.3%; p ¼ 0.022),
but that might rather be a by-chance ﬁnding.
STUDY LIMITATIONS. The main limitation of
BIOFLOW-II study is the small sample size that was
powered for the primary endpoint late lumen loss,
but not for clinical outcomes. As is common with
early randomized trials, our series is not presenting
an all-comers population, because for example, pa-
tients with acute myocardial infarction or 3-vessel
disease were excluded, as were those with complex
lesion morphologies such as heavy calciﬁcation, long
lesion length, ostial stenosis, vein graft disease, and
left main disease. Five-year outcomes of theall-comers BIOFLOW-III registry are expected to
cover this knowledge gap.
CONCLUSIONS
Five-year outcomes of the randomized, assessor-
blinded BIOFLOW-II study demonstrate the long-
term safety and performance of the biodegradable
polymer O-SES with a low TLF rates, similar to the
durable polymer X-EES, and no case of deﬁnite or
probable ST.
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PERSPECTIVES
WHAT IS KNOWN? Biodegradable polymer stents have
shown noninferiority to contemporary durable polymer
DES, but long-term data are scarce.
WHAT IS NEW? The BIOFLOW-II study presents
the ﬁrst 5-year data of the biodegradable polymer
O-SES and shows comparable clinical outcomes to
the durable polymer X-EES with absence of deﬁnite or
probable ST.
WHAT IS NEXT? The excellent outcomes of the
BIOFLOW-II study should be conﬁrmed in a larger series
of patients treated under real-world conditions, and
randomized trials should evaluate whether DAPT can be
shortened to 3 months.
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